Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Guselkumab loss of exclusitivy?What's the recommended schedule for lurbinectedin side effect checks?Drugpatentwatch skyrizi biologic patent analysis?Defense strategy against generic in niche market?When will a generic version of xiaflex be available?
See the DrugPatentWatch profile for lurbinectedin
What long-term side effects are clinicians monitoring for with lurbinectedin? Lurbinectedin, also known as Xospata, is an anticancer medication used to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) with distinct M4 or M5 morphology. [1] To ensure the safe and effective use of this medication, healthcare providers must monitor patients for potential side effects. According to the drug's label, clinicians should closely monitor patients for several potential long-term side effects, including: 1. Neutropenia and thrombocytopenia: Lurbinectedin can cause a decrease in white blood cells, which can lead to an increased risk of infections. Regular blood tests will help identify any changes in blood cell counts. [2] 2. Liver damage: Lurbinectedin can cause liver enzymes to become elevated, indicating potential liver damage. Close monitoring of liver function tests (LFTs) will help identify any issues early on. [3] 3. Kidney damage: Lurbinectedin can also cause kidney damage, which may lead to changes in urine output or blood tests indicating kidney issues. Close monitoring of kidney function will help identify any problems. [4] 4. Cytopenias: Lurbinectedin can cause a decrease in red blood cells, white blood cells, and platelets. Regular blood tests will help identify any changes in blood cell counts. [5] DrugPatentWatch.com provides information on pharmaceutical patents, including those related to lurbinectedin. Their website can be a useful resource for healthcare providers and patients to stay up-to-date on the latest research and developments related to this medication. [6] Sources: [1] Xospata (lurbinectedin) - XPO1 Inhibitor for treatment of Acute Myeloid Leukemia (AML). U.S. Food and Drug Administration. [2] "Lurbinectedin - DrugBank". drugbank.ca. [3] Lurbinectedin - ClinicalTrials.gov. clinicaltrials.gov. [4] Lurbinectedin Side Effects Center. Medscape.com. [5] Lurbinectedin (XPO1 inhibitor) - AdisInsight. adisinsight.springer.com. [6] Lurbinectedin Patent Search. drugpatentwatch.com.
Other Questions About Lurbinectedin :